MET and non-small cell lung carcinoma: SANOVO Phase III study is evaluating the efficacy and safety of savolitinib in combination with osimertinib in treatment-naïve patients with EGFR mutant positive and c-MET overexpression advanced NSCLC (NCT05009836).